The DNA repair proteins BECA1 and EECC1 as predictive markers In sporadic ovarian cancer

International Journal of Cancer

Volumn 124, Issue 4, 2009, Pages 806-815

  Weberpals, Jehamne ^a,b   Garbuio, Kyla ^b   O'Brien, Anna ^b   Clark Knewks, Katherine ^b   Doucette, Steve ^a   Antoniouk, Olga ^b   Gess, Glenwood ^b,c   Dimitreulakos, Jim ^b  

^a UNIVERSITY OF OTTAWA   (Canada)

^b OTTAWA HOSPITAL RESEARCH INSTITUTE   (Canada)

^c Division of Gynecologic Oncology   (Canada)

Author keywords

BRCAl; DNA repair; ERCC1; Predictive marker; Sporadic ovarian cancer

Indexed keywords

3 AMINOBENZAMIDE; BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; CYCLIN DEPENDENT KINASE 2 INHIBITOR; CYCLOPHOSPHAMIDE; EPIRUBICIN; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; HISTONE DEACETYLASE INHIBITOR; M 344; MESSENGER RNA; PACLITAXEL; TOPOTECAN; TUMOR MARKER; UNCLASSIFIED DRUG; ANTINEOPLASTIC AGENT; BRCA1 PROTEIN, HUMAN; DNA BINDING PROTEIN; ENDONUCLEASE; ERCC1 PROTEIN, HUMAN;

ADULT; ADVANCED CANCER; AGED; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER CELL CULTURE; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER SURGERY; CANCER SURVIVAL; CELL VIABILITY; CHEMOSENSITIZATION; CONTROLLED STUDY; DNA REPAIR; DOWN REGULATION; DRUG CYTOTOXICITY; DRUG EFFECT; DRUG EFFICACY; DRUG POTENTIATION; DRUG TARGETING; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VITRO STUDY; MAJOR CLINICAL STUDY; OVARY CANCER; PRIORITY JOURNAL; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RETROSPECTIVE STUDY; SALPINGOOOPHORECTOMY; BIOSYNTHESIS; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MIDDLE AGED; OVARY TUMOR; TUMOR SUPPRESSOR GENE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRCA1 PROTEIN; CARBOPLATIN; CISPLATIN; DNA REPAIR; DNA-BINDING PROTEINS; ENDONUCLEASES; FEMALE; GENES, BRCA1; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MIDDLE AGED; OVARIAN NEOPLASMS;

EID: 58149460399     PISSN: 00207136     EISSN: 10970215     Source Type: Journal    
DOI: 10.1002/ijc.23987     Document Type: Article

References (64)

1. Stewart DJ. Mechanisms of resistance to cisplatin and carboplatin. Crit Rev Oncol Hematol 2007;63:12-31.
2. Quinn JE. James CR. Stewart GE. Mulligan JM, White P, Chang GK. Mullan PB, Johnston PG, Wilson RH, Harkin DP. BRCAl mRNA expression levels predict for overall survival in ovarian cancer after chemotherapy. Clin Cancer Res 2007; 13:7413-20.
3. Taron M, Rosell R, Felip E, Mendez P, Souglakos J, Ronco MS, Queralt C, Majo J, Sanchez JM, Sanchez JJ, Maestre J. BRCAl mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Moi Genet 2004; 13:2443-9.
4. Dabholkar M, Vionnet J, Bostick-Bruton F, Yu JJ, Reed E. Messenger RNA levels of XPAC and ERCCl in ovarian cancer tissue correlate with response to platinum-based chemotherapv. J Clin Invest 1994;94:703-8.
5. Quinn JE, Kennedy RD, Mullan PB, Gilmore PM, Carty M, Johnston PG, Harkin DP. BRCAl functions as a differential modulator of chemotherapy-induced apoptosis. Cancer Res 2003;63:6221-8.
6. Danger R, Specht K, Becker K, Ewald P, Bekesch M, Sarbia M, Busch R, Feith M, Stein HJ, Siewert JR, Holler H. Association of pre-therapeutie expression of chemotherapy-related genes with response to neoadjuvant chemotherapy in Barrett carcinoma. Clin Cancer Res 2005;11:7462-9.
7. Matloff ET. The breast surgeon's role in BRCA 1 and BRCA2 testing. Am J Surg 2000; 180:294-8.
8. Hilton JL, Geisler JP, Rathe JA, Hattermann-Zogg MA, DeYoung B, Buller RE. Inactivation of BRCAl and BRCA2 in ovarian cancer. J Natl Cane Inst 2002;94:1396-406.
9. Thrall M, Gallion HH, Kryscio R, Kapali M, Armstrong DK, DeLoia JA. BRCAl expression in a large series of sporadic ovarian carcinomas: a Gvnecoiogic Oncology Group study. Int J Gynecol Cancer 2006;(16Suppl)1:l66-71.
10. Turner N, Tutt A, Ashworth A. Hallmarks of 'BRCAness' in sporadic cancers. Nat Rev 2004;4:814-19.
11. Weberpals JI, Clark-Knowles KV, Vanderhyden BC. Sporadic epithelial ovarian cancer: clinical relevance of BRCAl inhibition in the DNA damage and repair pathway. J Clin Oncol 2008;26:3259-67.
12. Sirisabya N, Manchana T, Termrangreunglert W, Triratanachat S, Charuruks N, Tresukosol D. Prevalence of BRCAl expression in epi-thelial ovarian cancer: immunohistochemical study. J Med Assoc Thai 2007;90:9-14.
13. Rosell R, Skrzypski M, Jassem E, Taron M, Bartolucci R, Sanchez JJ, Mendez P, Chaib I, Perez-Roca L, Szymanowska A, Rzyman W, Puma F, et al. BRCAl: a novel prognostic factor in resected non-small-cell lung cancer. PLoS ONE 2007;2:e l129.
14. Lambie H, Miremadi A, Pinder SE, Bell JA, Wencyk P, Paish EC, Macraillan RD, Ellis 10. Prognostic significance of BRCAl expression in sporadic breast carcinomas. J Pathol 2003;200:207-13.
15. Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danen-berg KD, Groshen S, TsaoA-Wei DD, Danenberg PV, Lenz HJ. ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy. J Clin Oncol 2001:19:4298-304.
16. Metzger R, Leichman CG, Danenberg KD, Danenberg PV, Lenz HJ, Hayashi K, Groshen S, Salonga D, Cohen H, Laine L, Crookes P, Sil-berman H, et al. ERCC1 mRNA levels complement thymidylate synthase mRNA levels in predicting response and survival for gastric-cancer patients receiving combination cisplatin and fluorouracil chemotherapy. J Clin Oncol 1198; 16:309-16.
17. Joshi MB, Shirota Y, Danenberg KD, Conlon DH, Salonga DS, Hern-don JE II, Danenberg PV, Harpole DH Jr. High gene expression of TS1, GSTP1, and ERCC1 are risk factors for survival in patients treated with trimodality therapy for esophageal cancer. Clin Cancer Res 2005;11:2215-21.
18. Handra-Luca A, Hernandez J, Mountzios G, Taranchon E, Lacau-St-Guiiy J, Soria JC, Fouret P. Excision repair cross complementation group 1 immunohistochemical expression predicts objective response and cancer-specific survival in patients treated by Cisplatin-based induction chemotherapy for locally advanced head and neck squamous cell carcinoma. Clin Cancer Res 2007; 13:3855-9.
19. Lord RV, Brabender J, Gandara D, Alberola V, Camps C, Doraine M, Cardenal F, Sanchez JM, Gumerlock PH, Taron M, Sanchez JJ, Danenberg KD, et al. Low ERCC1 expression correlates with prolonged survival after cisplatin plus gemcitabine cheraotherapv in non-small cell lung cancer. Clin Cancer Res 2002;8:2286-91.
20. Rosell R, Lord RV, Taron M, Reguart N. DNA repair and cisplatin resistance in non-small-ceil lung cancer. Lung Cancer 2002;38:217-27.
21. Bepler G, Kusmartseva I, Sharma S, Gautam A, Cantor A, Sharma A, Simon G. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol 2006;24:4731-7.
22. Dabholkar M, Bostick-Bruton F, Weber C, Bohr VA, Egwuagu C, Reed E. ERCC1 and ERCC2 expression in malignant tissues from ovarian cancer patients. J Natl Cane Inst 1992;84:1512-17.
23. Darcy KM, Tian C, Reed E. A Gynecologic Oncology Group study of platinum-DNA adducts and excision repair cross-complementation group 1 expression in optimal, stage III epithelial ovarian cancer treated with platinum-taxane chemotherapy. Cancer Res 2007;67:4474-81.
24. Yarden RI, Papa ML. BRCAl at the crossroad of multiple cellular pathways: approaches for therapeutic interventions. Mol Cancer Ther 2006;5:1396-404.
25. Dantzer F, Schreiber V, Niedergang C, Trucco C, Flatter E, De La Rubia G, Oliver J, Rolli V, Menissier-de Murcia J, de Murcia G. Involvement of polv(ADP-ribose) polvmerase in base excision repair. Biochimie 1999;81:69-75.
26. Deans AJ, Khanna KK, McNees CJ, Mercuric C, Heierhorst J, McAr-thur GA. Cyclin-Dependent Kinase 2 Functions in Normal DNA Repair and Is a Therapeutic Target in BRCA 1-Deficient Cancers. Cancer Res 2006;66:8219-26.
27. Garber K. HDAC inhibitors overcome first hurdle. Nat Biotechnol 2007;25:17-19.
28. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Giabbeke M, van Oosterom AT, Christian MC, Gwyther SG. New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cane Inst 2000;92:205-16.
29. Kroupis C, Stathopoulou A, Zygalaki E, Ferekidou L, Talieri M, Lia-nidou ES. Development and applications of a real-time quantitative RT-PCR method (QRT-PCR) for BRCAl mRNA. Clin Biochem 2005;38:50-7.
30. Behrens BC, Hamilton TC, Masuda H, Grotzinger KR. Whang-Peng J, Louie KG, Knutsen T, McKoy WM, Young RC, Ozols RF. Characterization of a cis-diaraminedichloroplatinum(II)-resistant human ovarian cancer ceil line and its use in evaluation of platinum analogues. Cancer Res 1987;47:414-18.
31. Winter WE III, Maxwell GL, Tian C, Carlson JW, Ozols RF, Rose PG, Markman M, Armstrong DK, Muggia F, McGuire WP. Prognostic factors for stage III epithelial ovarian cancer; a Gynecologic Oncology Group Study. J Clin Oncol 2007;25:3621-7.
32. Shoemaker RH. The NCI60 human tumour cell line anticancer drug screen. Nat Rev Cancer 2006;6:813-23.
33. Bast RC Jr, Klug TL, St John E, Jenison E, Niloff JM, Lazarus H, Berkowitz RS, Leavitt T, Griffiths CT, Parker L, Zurawski VR Jr, Knapp RC. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer. N Engl J Med 1983;309:883-7.
34. Gilani MM, Karimi Zarchi M, Ghaeramaghami F, Behtash N, Mousavi AS, Ansaripoor S. A study to evaluate the utility of presurgi-cal CA125 to predict optimal tumor cytoreduction of epithelial ovarian cancer. Gynecol Oncol 2007;105:780-3.
35. Husain A, He G, Venkatraraan ES, Spriggs DR. BRCAl up-regulation is associated with repair-mediated resistance to cis-diamminedichlor-opiatinum(II). Cancer Res 1998:58:1120-3.
36. Clark-Knowles KV, Garson K, Jonkers J, Vanderhyden BC. Conditional inactivation of Brcal in the mouse ovarian surface epithelium results in an increase in preneoplastic changes. Exp Cell Res 2007; 313:133-45.
37. Xing D, Orsulic S. A mouse model for the molecular characterization of brcal-associated ovarian carcinoma. Cancer Res 2006;66:8949-53.
38. Sylvain V, Lafarge S, Bignon YJ. Dominant-negative activity of a Brcal truncation mutant: effects on proliferation, tumorigenicity in vivo, and cheraosensitivity in a mouse ovarian cancer cell line. Int J Oncol 2002;20:845-53.
39. Chabalier C, Lamare C, Racca C, Privat M, Valette A, Larminat F. BRCAl downregulation leads to premature inactivation of spindle checkpoint and confers paclitaxel resistance. Cell Cvcle 2006;5: 1001-7.
40. Wang RH, Yu H, Deng CX. A requirement for breast-cancer-associated gene 1 (BRCA 1) in the spindle checkpoint. Proc Natl Acad Sci US A 2004;101:17108-13.
41. Bae 1, Rih JK, Kim HJ, Rang HJ, Haddad B, Kirilyuk A, Fan S, Avan-taggiati ML, Rosen EM. BRCAl regulates gene expression for orderly mitotic progression. Cell Cycle 2005;4:1641-66.
42. Tassone P. Tagliaferri P, Perricelli A, Blotta S. Quaresima B. Mar-telli ML, Goel A, Barbieri V, Costanzo F, Boiand CR, Venuta S. BRCAl expression modulates chemosensitivity of BRCAl-defective HCC1937 human breast cancer ceils. Br J Cancer 2003:88: 1285-91.
43. Selvakumaran M, Pisarcik DA, Bao R, Yeung AT, Hamilton TC. Enhanced cisplatin cytotoxicity by disturbing the nucleotide excision repair pathway in ovarian cancer cell lines. Cancer Res 2003:63: 1311-16.
44. Azuma K, Komohara Y, Sasada T, Terazaki Y, Ikeda J, Hoshino T, Itoh K, Yamada A, Aizawa H. Excision repair cross-complementation group 1 predicts progression-free and overall survival in non-small cell lung cancer patients treated with platinum-based chemotherapy. Cancer Sci 2007;98:1336-43.
45. Booton R, Ward T, Ashcroft L, Morris J, Heighway J, Thatcher N. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer. J Thorac Oncol 2007;2:902-6.
46. Wachters FM, Wong LS, Timens W, Kampinga HH, Groen HJ. ERCC 1, hRad51, and BRCA 1 protein expression in relation to tumour response and survival of stage III/IV NSCLC patients treated with chemotherapy. Lung Cancer 2005;50:211-19.
47. Cobo M, Isla D, Massuti B, Montes A, Sanchez JM, Provencio M, Vinolas N, Paz-Ares L, Lopez-Vivanco G, Munoz MA, Felip E, Alberola V, et al. Customizing cisplatin based on quantitative excision repair cross-complementing 1 mRNA expression: a phase III trial in non-small-cell lung cancer. J Clin Oncol 2007;25;2747-54.
48. Zheng Z, Chen T, Li X, Haura E, Sharma A, Bepler G. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med 2007:356:800-8.
49. Lee KH, Min HS, Han SW, Oh DY, Lee SH, Kim DW, Ira SA, Chung DH, Kim YT, Kim TY, Heo DS, Bang YJ, et al. ERCC1 expression by immunohistochemistry and EGFR mutations in resected non-small cell lung cancer. Lung Cancer 2008:60:401-7.
50. Simon GR, Sharma S, Cantor A, Smith P, Bepler G. ERCC1 expression is a predictor of survival in resected patients with non-small cell lung cancer. Chest 2005; 127:978-83.
51. Niedernhofer LJ, Odijk H, Budzowska M, van Drunen E, Maas A, Theil AF, de Wit J, Jaspers NG, Beverloo HB, Hoeijmakers JH, Kanaar R. The structure-specific endonuclease Ercc 1 -Xpf is required to resolve DNA interstrand cross-link-induced double-strand breaks. Mol Cell Biol 2004;24:5776-87.
52. Deeb KK, Michalowska AM, Yoon CY, Krummey SM, Hoenerh-off MJ, Kavanaugh C, Li MC, Demayo FJ, Linnoila I, Deng CX, Lee EY, Medina D, et al. Identification of an integrated SV40 T/t-antigen cancer signature in aggressive human breast, prostate, and lung carcinomas with poor prognosis. Cancer Res 2007:67:8065-80.
53. Tait DL, Obemiiller PS, Redlin-Frazier S, Jensen RA, Welcsh P, Dann J, King MC, Johnson DH, Holt JT. A phase I trial of retroviral BRCAlsv gene therapy in ovarian cancer. Clin Cancer Res 1997:3: 1959-68.
54. Tait DL, Obermiller PS, Hatmaker AR, Redlin-Frazier S, Holt JT. Ovarian cancer BRCAl gene therapy: Phase I and II trial differences in immune response and vector stability. Clin Cancer Res 1999;5: 1708-14.
55. Ramalingam SS, Parise RA, Ramanathan RK, Lagatfuta TF, Mus-guire LA, Stoller RG, Potter DM, Argiris AE, Zwiebel JA, Egorin MJ, Belani CP. Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies. Clin Cancer Res 2007; 13:3605-10.
56. Sin LL, Pili R, Duran 1, Messersmith WA, Chen EX, Sullivan R, MacLean M, King S, Brown S, Reid GK, Li Z, Kalita AM, et al. Phase I study of MGCD0103 given as a three-times-per-week oral dose in patients with advanced solid tumors. J Clin Oncol 2008;26: 1940-7.
57. Olsen EA, Kim YH, Kuzel TM, Pacheco TR, Foss FM, Parker S, Frankel SR, Chen C, Ricker JL, Arduino JM, Duvic M. Phase Tib mul-ticenter trial of vorinostat in patients with persistent, progressive, or treatment refractory cutaneous T-cell lymphoma. J Clin Oncol 2007;25:3109-15.
58. Bochar DA, Wang L, Beniya H, Kinev A, Xue Y, Lane WS, Wang W, Kashanchi F, Shiekhattar R. BRCAl is associated with a human SWT/SNF-related complex: linking chromatin remodeling to breast cancer. Cell 2000; 102:257-65.
59. Monteiro AN, August A, Hanafusa H. Evidence for a transcriptional activation function of BRCAl C-terminal region. Proc Nati Acad Sci USA 1996;93:13595-9.
60. Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford JM, Buggy JJ. HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination. Proc Natl Acad Sci USA 2007; 104: 19482-7.
61. Bryant HE, Schultz N, Thomas HD, Parker KM, Flower D, Lopez E, Kyle S, Meuth M, Curtin NJ, Helleday T. Specific killing of BRCA2-deficient tumours with inhibitors of poiv(ADP-ribose) polymerase. Nature 2005;434:913-17.
62. Farmer H, McCabe N, Lord CJ, Tutt AN, Johnson DA, Richardson TB, Santarosa M, Dillon KJ, Hickson I, Knights C, Martin NM, Jackson SP, et al. Targeting the DNA repair defect in BRCA mutant eel Is as a therapeutic strategy. Nature 2005;434:917-21.
63. Brustmann H. Poly(adenosine diphosphate-ribose) polymerase expression in serous ovarian carcinoma: correlation with p53. MIB-1, and outcome. Int J Gynecol Pathol 2007;26:147-53.
64. Clark G. Prognostic factors versus predictive factors: examples from a clinical trial of erlotinib. Mol Oncol 2008;1:406-12.